Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05139368 · ClinicalTrials.gov registry record · NA

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer

A NA study of Endometrial Carcinoma and Cervical Carcinoma, sponsored by University of Utah.

Active
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT05139368 is a NA study of Endometrial Carcinoma and Cervical Carcinoma that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 22 participants, below the 390-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05139368, a NA study of Endometrial Carcinoma and Cervical Carcinoma, is active but no longer recruiting, sponsored by University of Utah.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies the feasibility of using hypo-fractionated radiotherapy for the treatment of cervical or endometrial cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Interventions

  • RADIATION Hypofractionated Radiation Therapy

Study Locations (1)

Utah

  • Huntsman Cancer Institute/University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2021-11-11
Est. Completion 2027-06-26
Phase NA

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT05139368

The ClinicalTrials.gov registry entry for NCT05139368 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 390-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (94% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Endometrial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Hypofractionated Radiation Therapy is the first listed.

NCT05139368 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT05139368 about?

NCT05139368 is a clinical study titled "Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer". This clinical trial studies the feasibility of using hypo-fractionated radiotherapy for the treatment of cervical or endometrial cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effec...

What is the current status of trial NCT05139368?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2021-11-11. Estimated completion is 2027-06-26.

What conditions does trial NCT05139368 study?

This clinical trial studies the following conditions: Endometrial Carcinoma, Cervical Carcinoma.

What interventions are being tested in trial NCT05139368?

The interventions under investigation include: Hypofractionated Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT05139368?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05139368 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.